WO2007028117A3 - P8 as a marker for heart failure - Google Patents

P8 as a marker for heart failure Download PDF

Info

Publication number
WO2007028117A3
WO2007028117A3 PCT/US2006/034405 US2006034405W WO2007028117A3 WO 2007028117 A3 WO2007028117 A3 WO 2007028117A3 US 2006034405 W US2006034405 W US 2006034405W WO 2007028117 A3 WO2007028117 A3 WO 2007028117A3
Authority
WO
WIPO (PCT)
Prior art keywords
heart failure
marker
diagnosis
treatment
present
Prior art date
Application number
PCT/US2006/034405
Other languages
French (fr)
Other versions
WO2007028117A2 (en
Inventor
John M Kyriakis
Sandro Goruppi
Original Assignee
New England Medical Center Inc
John M Kyriakis
Sandro Goruppi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New England Medical Center Inc, John M Kyriakis, Sandro Goruppi filed Critical New England Medical Center Inc
Publication of WO2007028117A2 publication Critical patent/WO2007028117A2/en
Publication of WO2007028117A3 publication Critical patent/WO2007028117A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Electrotherapy Devices (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention is related to the diagnosis and treatment of p8-related conditions, particularly heart failure.
PCT/US2006/034405 2005-09-02 2006-09-01 P8 as a marker for heart failure WO2007028117A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71406705P 2005-09-02 2005-09-02
US60/714,067 2005-09-02

Publications (2)

Publication Number Publication Date
WO2007028117A2 WO2007028117A2 (en) 2007-03-08
WO2007028117A3 true WO2007028117A3 (en) 2007-10-18

Family

ID=37809631

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/034405 WO2007028117A2 (en) 2005-09-02 2006-09-01 P8 as a marker for heart failure

Country Status (1)

Country Link
WO (1) WO2007028117A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002062205A2 (en) * 2001-02-07 2002-08-15 The General Hospital Corporation Methods for diagnosing and treating heart disease
US6852509B1 (en) * 1996-10-29 2005-02-08 Laurent Bracco Anti-P53 single-chain antibody fragments and their uses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6852509B1 (en) * 1996-10-29 2005-02-08 Laurent Bracco Anti-P53 single-chain antibody fragments and their uses
WO2002062205A2 (en) * 2001-02-07 2002-08-15 The General Hospital Corporation Methods for diagnosing and treating heart disease

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
IOVANNA: "Expression of the stress-associated p8 is a requisite for tumor development", INT. J. GASTROINTEST. CANCER, vol. 31, no. 1-3, 2002, pages 89 - 98 *
NAKAMURA ET AL.: "Fas-Mediated Apoptosis in Adriamycin-Induced Cardiomyopathy in Rats", VIVO STUDY, vol. 102, August 2000 (2000-08-01), pages 572 - 578 *
RAPISARDA ET AL.: "Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway", CANCER RESEARCH, vol. 62, August 2002 (2002-08-01), pages 4316 - 4324, XP002280284 *
VASSEUR ET AL.: "p8-deficient fibroblasts grow more rapidly and are more resistant to adriamycin-induced apoptosis", ONCOGENE, vol. 21, March 2002 (2002-03-01), pages 1685 - 1694 *

Also Published As

Publication number Publication date
WO2007028117A2 (en) 2007-03-08

Similar Documents

Publication Publication Date Title
WO2006089871A3 (en) Diphenylurea derivatives useful as erg channel openers for the treatment of cardiac arrhythmias
WO2007018314A3 (en) Therapeutic agent for diabetes
WO2008076046A8 (en) Novel 2-amino-5, 5-diaryl-imidazol-4-ones
WO2009064388A3 (en) Inhibitors of human methionine aminopeptidase 1 and methods of treating disorders
WO2007093627A3 (en) Biocidal composition
WO2011028947A3 (en) Heterocyclic compounds for the inhibition of pask
WO2007137071A3 (en) Compositions of r(+) and s(-) pramipexole and methods of using the same
WO2011106322A3 (en) Biomarkers for acute ischemic stroke
WO2003094856A3 (en) 1l1rl-1 as a cardiovascular disease marker and therapeutic target
MY145439A (en) Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
WO2008006535A3 (en) Use of a cationic colloidal preparation for the diagnosis and treatment of ocular diseases
UA94580C2 (en) 39-desmethoxyrapamycin analogue with increased blood-brain barrier permeability for the treatment of a medical condition resulting from neural injury or disease
WO2009111633A3 (en) Mercaptan and seleno-mercaptan compounds and methods of using them
WO2011039735A3 (en) Compounds with ddx3 inhibitory activity and uses thereof
WO2008149353A3 (en) Telomerase activating compounds and methods of use thereof
WO2006076370A3 (en) Substituted cyclopentanes or cyclopentanones for the treatment of ocular hypertensive conditions
WO2009124330A3 (en) Treatment of tumors
WO2007051785A3 (en) Use of sdf-1 for the treatment and/or prevention of neurological diseases
WO2009074247A8 (en) Novel 2-aryl-thiazole-4-carboxamide derivatives, production thereof, and use thereof as a medicament
WO2009124962A3 (en) Sulfonamides
WO2009041663A1 (en) Agent for prevention and/or treatment of skin diseases
WO2007144057A3 (en) Antimicrobial carbon
WO2007038264A3 (en) Gapr-1 methods
EA200900261A1 (en) USE OF ESCIN
WO2007131907A3 (en) 1h-indol-5-yl-piperazin-1-yl-methanone derivatives

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06790155

Country of ref document: EP

Kind code of ref document: A2